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CD55, CD59, CD46, and CD35 are proteins with complement regulatory (Creg) properties that ensure cell and tissue integrity
when this system is activated. The aim of this study was to evaluate the Creg expression on peripheral blood cells from SLE
patients and its association with cytopenia and disease activity. Flow cytometric analyses were performed on blood cells from
100 SLE patients and 61 healthy controls. Compared with healthy controls, we observed in SLE patients with lymphopenia and
neutropenia decreased expression of CD55, CD59, and CD46 (P<0.05). In SLE patients with anemia, CD59 and CD35 were
decreased on red blood cells. Furthermore, there was a negative correlation between CD55 and CD59 on neutrophils and the
disease activity. The results suggest there is an altered pattern of Creg expression on the peripheral blood cells of SLE patients, and
the expression is correlated with disease activity and/or with activation of the complement system.
1.Introduction
The complement system (CS) represents the ﬁrst defense
line of innate immunity; it acts facilitating the phagocytosis
of immune complexes, pathogens, and apoptotic cells and
forming the membrane attack complex (MAC), resulting
in cell lysis. This powerful defense system is composed of
multiple components (>60 diﬀerent proteins and activation
products) that trigger in a cascade-type system [1].
The complement as a central defense system is imme-
diately activated within seconds upon entry of a pathogen
into the human host through three pathways: the classical
(triggered by antibody-antigen complexes), the lectin (trig-
gered by carbohydrates on the surface of bacteria), and the
alternative pathways (spontaneous and continuous process
which is initiated by the conformational change of C3).
These three pathways use diﬀerent proteins to produce C3
and C5 convertases, which involve cleavage of C2 and C4
(classical and lectin pathway) or the cleavage of factor B by
factor D (alternative pathway). All result in the formation
of the lytic MAC (membrane-attack complex: C5b-9) [2,
3]. Activation of the complement system is a powerful
drive to initiate inﬂammation but can, if unregulated,
lead to severe tissue damage and disease. Based on their
potent damaging capacity, the generation and targeting of
complement eﬀector compounds are tightly regulated [4].
Normal cell membranes express complement regulatory
(Creg) proteins that regulate activation of the comple-
ment system and provide essential protection against self-
damage [5]. There are four major human cell surface Creg2 Clinical and Developmental Immunology
proteins: CD59 (membrane inhibitor of reactive lysis—
MIRL), which is a complement membrane inhibitor that
blocks assembly of the MAC by binding to C8 and C9 [6],
CD55 (decay accelerating factor—DAF), which accelerates
the disassembly of preformed C3 and C5 convertases [7],
CD46 (membrane cofactor protein), which acts as a cofactor
for the factor-I-mediated cleavage of the activated comple-
ment components C3b/C4b [8], and CD35 (complement
receptortypeI,CR1),whichisalsoinvolvedintheregulation
of C3 fragment deposition and serves as a cofactor for the
degradation of C3b by factor I [4]. These Creg proteins are
present on the cell surface of whole blood cells, except the
CD46, which is not expressed on RBCs. It has been reported
that the production and the expression of some of these
complement regulatory proteins are altered in autoimmune
diseases and that inherited deﬁciencies of the complement
system components are associated with a high prevalence
of systemic lupus erythematosus (SLE), glomerulonephritis,
and vasculitis [9–11].
The complement system is integrally involved in the
pathogenesis of tissue injury in SLE. Tissue deposition of
immunoglobulin is a characteristic feature of SLE and can
causecontinuedcomplementactivationbytheclassicalpath-
way [10]. Therefore, potential diﬀerences on the expression
of the Creg proteins could implicate diﬀerent susceptibilities
to complement-mediated damage and be clinically signiﬁ-
cant. Particularly, altered expression on blood cells could be
related to cytopenic changes common in this disease. Earlier
studies have shown that expression of CD35 [12–16], CD55,
andCD59[17,18]onerythrocytesandCD55andCD59[19–
21] on lymphocytes are decreased in patients with SLE, but
some of these ﬁndings were controversial. The current study
aimed to evaluate the expression of CD55, CD59, CD46,
and CD35 expression on peripheral blood cells from SLE
and healthycontrols using ﬂow cytometry and its correlation
with cytopenias on these patients.
2.MaterialandMethods
2.1. Subjects. One hundred patients that fulﬁlled the Amer-
ican College of Rheumatology classiﬁcation criteria [22]f o r
SLE and 61 healthy controls with no history of autoimmune
diseases were included in the present study. SLEDAI (SLE
disease activity index) [23] and SLICC (systemic lupus
international collaborating clinics) damage index [24]w e r e
applied to each patient as a measurement of disease activity
and cumulative damage, respectively.
SLE patients were followed up at the Rheumatology
Clinic of Hospital de Cl´ ınicas de Porto Alegre, Brazil. The
exclusioncriterionwasconcomitantpresenceofoverlapwith
another autoimmune disease. Peripheral blood samples were
collected in Na-EDTA Vacutainer tubes. All SLE patients
were receiving an immunosuppressive drug at the time
of blood collection (mycophenolate mofetil, cyclophos-
phamide, azathioprine, methotrexate, cyclosporine, and/or
rituximab).
This study was performed with approval of the ethics
committeeoftheHospitaldeCl´ ınicasdePortoAlegre,andall
subjects were informed about the objectives and procedures
of the study and gave their written informed consent.
2.2. Flow Cytometric Analysis of CD55, CD59, CD35, and
CD46 on the Cell Membrane. For red blood cell (RBC)
staining, 100uL of diluted blood (with an optimal di-
lution with phosphate-buﬀered saline (PBS) to achieve
10000RBC/uL) as placed into polystyrene tubes (Becton
Dickinson (BD) Biosciences, San Diego, CA, USA) and as
subjected to two-colour staining with 8uL/test of ﬂuoro-
chrome-conjugated monoclonal antibodies (MoAbs) against
CD55PE, CD59FITC, CD35PE, and CD46FITC (BD Bio-
sciences, San Diego, CA, USA). After 20min incubation at
room temperature, samples were resuspended in 0.5mL of
PBS and cells were analysed on the ﬂow cytometer.
For leukocyte staining, 100uL of whole blood (with an
optimal dilution to achieve 5000cells/uL) as placed into
polystyrene tubes and as subjected to two-colour stain-
ing with 8uL of each antibody of ﬂuorochrome-conju-
gated MoAbs against CD55PE, CD59FITC, CD35PE and
CD46FITC (BD Biosciences, San Diego, CA, USA). After
15min incubation at room temperature, 1.0mL of FACSlyse
(BD Biosciences, San Diego, CA, USA) was added and lysis
was allowed for 10min at room temperature. Samples were
washed once and resuspended in 0.5mL of PBS.
50000 events were acquired and analysed on a FAC-
SCalibur ﬂow cytometer using CellQuest software (BD
Biosciences, San Diego, CA, USA). Membrane intensity of
CD55, CD59, CD46, and CD35, which is proportional to
the number of CD55, CD59, CD46 and CD35 epitopes on
the membrane, was estimated in the gated subpopulations
by one-parameter histograms, and the relative mean ﬂu-
orescence intensity (MFI) was recorded. The deﬁnition of
positive and negative cells was set when staining with isotype
control was performed, in order to set the gates and distin-
guish positive staining from autoﬂuorescence and nonspecif-
ic antibody binding.
2.3. Serological Studies. Measurement of complement 3 (C3)
and complement 4 (C4) is used to determine whether
primary deﬁciencies or activation-related consumption of
the complement components is present in SLE patients. C3
and C4 measurements were performed using the ADVIA
1800 chemical analyzer system (Siemens) on patient’s sera.
2.4. Complete Blood Cell Count (CBC). AC B Cw a sp e r -
formed using the Sysmex XE-2100 (Sysmex Corporation,
Japan). Slides revised were prepared with SP-100 SYSMEX
using a staining program was as follows: May-Gr¨ unwald (Bio
Lyon, France) pure time: 2.5min, MG dilute time: 3min,
Giemsa (Bio Lyon, France) time: 7min, rinse 0min, and
drying time 5min, as instructed by the supplier.
2.5.Statistics. DatawerecomparedusingtheMann-Whitney
U test, Student’s t-test, and Spearman’s correlation coeﬃ-
cient when appropriate. The level of statistical signiﬁcance
wasestablishedatP<0.05.Statisticalanalysiswasconducted
using SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA).Clinical and Developmental Immunology 3
Table 1: Demographic, clinical, and laboratory features of SLE patients.
Patients’ features SLE (n = 100) Healthy controls (n = 61)
Females (%) 93 67.2
Age (year) median (interquartile range) 42 (31–53) 45 (30–61)
SLEDAIa median (interquartile range) 2 (0–5) —
SLICC-DIb median (interquartile range) 1 (0–2) —
Malar rash (%) 58 —
Nephritis (%) 45 —
Arthritis (%) 67 —
AIHAc (%) 28 —
RBC (×1012 cells/uL) 4.15 (0.55)d 4.4 (0.36)
Hemoglobin (g/dL) 12.0 (1.6)d 13.5 (1.2)
Platelets (×103 cells/uL) 208 (65)d 228 (45)
Leucocytes (×103 cells/uL) 5.43 (4.07–7.91)e 6.96 (6–8.59)
Lymphocytes (×103 cells/uL) 1.32 (0.85–1.79)e 2.25 (1.75–2.85)
Neutrophils (×103 cells/uL) 3.58 (2.22–5.29)e 3.77 (3.08–4.74)
Monocytes (×103 cells/uL) 0.48 (0.37–0.68)e 0.58 (0.6–0.75)
Thrombocytopenia∗ (%) 16 0
Leukopenia∗ (%) 17 0
Lymphopenia∗ (%) 38 0
Neutropenia∗ (%) 13 0
Anemia∗ (%) 21 0
C4 level 25.4 (16.8) —
C3 level 108.4 (28.1) —
aSLEDAI: systemic lupus erythematosus disease activity index.
bSLICC-DI: systemic lupus international collaborating clinics damage index.
cAIHA: autoimmune hemolytic anemia (positive Coombs’ test).
dMean ± SD.
eMedian (interquartile range).
∗Lymphopenia: <1200lymphocytes/uL, neutropenia: <1500neutrophils/uL, anemia: hemoglobin < 11g/dL, and thrombocytopenia: platelets <
150.000cells/uL.
3. Results
The description of the 100 patients and 61 healthy controls
is summarized in Table 1. Of the SLE patients, 38% had
lymphopenia (lymphocytes: <1200/uL), 13% had anemia
(hemoglobin < 11g/dL), 21% had neutropenia (neutrophils
< 1500/uL), and 16% had thrombocytopenia (platelets <
150.000/uL). These disease manifestations and cell counts
were at the time the blood sample was taken, and the
patients were not subdivided by the number of cytopenic
manifestations. None of these cytopenias were observed in
the healthy control group.
3.1. Neutrophil Analyses. In SLE patients, the MFIs of all
Cregs on neutrophils (granulocytes) were signiﬁcantly lower
than those of healthy controls (Table 2). When comparing
neutropenic (13/100) with non-neutropenic SLE patients,
all Cregs, with the exception of CD46, were signiﬁcantly
decreased (Figure 1).
There was a negative correlation between CD55 (r =
−0.278,P = 0.019) and CD59 (r =− 0.23,P = 0.048)
expression on neutrophils and the SLEDAI; beside that, there
was a positive correlation between CD55 (r = 0.237,P =
0.021) and CD35 (r = 0.334,P = 0.030) expression on
neutrophils and C3 serum levels in SLE patients, and CD55
(r = 0.334,P = 0.001) with C4 level.
WhenanalyzingonlyneutropenicSLEpatients,apositive
correlation was shown between CD59 on neutrophils and C4
serum levels (r = 0.828,P = 0.006).
3.2.LymphocyteAnalyses. InSLEpatients,theMFIsofCD55,
CD59, and CD46 on lymphocytes were signiﬁcantly lower
than those of healthy controls (Table 2). When comparing
lymphopenic (38/100) with non-lymphopenic SLE patients,
onlyCD55andCD59weresigniﬁcantlydecreased(Figure 2).
There was a positive correlation between CD55 (r =
0.231,P = 0.026) expression on lymphocytes and C3 serum
levels in SLE patients, and no association with SLEDAI or
SLICC.
3.3. Monocyte Analyses. In SLE patients, only the MFI of
CD55 on monocytes was signiﬁcantly lower than that of
healthy controls (Table 2). There was no correlation between
Creg expression on monocytes and C3 and C4 level or
SLEDAI and SLICC in SLE patients.4 Clinical and Developmental Immunology
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Figure 1: Creg surface expression of neutrophil cell. The ﬁgure displays mean ﬂuorescence intensity (MFI) of CD55, CD59, CD46, and
CD35 on gated neutrophil from SLE patients with neutropenia, without neutropenia and controls. Median and interquartile range from all
subjects studied in each group were shown. ∗Signiﬁcant statistical diﬀerence (P<0.05).
3.4. Red Blood Cell Analyses. In SLE patients, the MFIs of
CD59 and CD35 on RBC were signiﬁcantly lower than
those of healthy controls (Table 2). When comparing anemic
(21/100) with nonanemic SLE patients, there were no MFI
CD59 and CD35 statistic diﬀerence (Figure 3).
There was a positive correlation between CD35 (r =
0.218,P = 0.049) expression on RBC and C4 serum levels
in SLE patients and no association with SLEDAI or SLICC.
When analyzed only anemic patients, this latter correlation
was stronger (r = 0.526,P = 0.021). CD46 was not analyzed
because it is not expressed on RBCs.
4. Discussion
Our study revealed signiﬁcantly lower Creg expression on
several blood cells from SLE patients when compared with
healthy controls, more marked in cytopenic patients, and
in many cases associated with higher disease activity and
lower serum C3 and C4 levels. Although there are a few
publications evaluating some of the Creg proteins in speciﬁc
bloodcellsinSLEpatients,ourstudyistheﬁrsttoencompass
all the membrane-bound Cregs and all blood cells in a large
sample of SLE patients. This allows a clear view of the
expression proﬁle of these proteins and their relations with
decreased blood cell numbers and with disease activity.
We have previously reported a decreased expression
of CD55 (but not of CD59) on neutrophils from SLE
patients[21],anddecreasedCD35expressiononneutrophils
has also been shown [16, 25]. In this study, beside con-
ﬁrming the decreased expression of CD55 and CD59, it
was demonstrated that the higher the disease activity, the
lower their expression on neutrophils. Furthermore, there
might be a direct correlation between the lower CD55 and
CD35 expression and activation of the classical complement
pathway, as indicated by the lower C3 and C4 serum levels.
These ﬁndings suggest that the decreased expression of CregsClinical and Developmental Immunology 5
Table 2: The mean of membrane ﬂuorescence intensity (MFI) of CD55, CD59, CD46, and CD35 on the blood cells of SLE patients and
controls.
Cell Creg SLE patient Control Pb
MFIa MFIa
Neutrophils
CD55 515 ± 132 611 ± 168 0.001∗
CD59 61 ± 24 68 ± 15 0.034∗
CD35 88 (67–154) 138 (86–185) 0.007∗
CD46 97 ± 21 113 ±19 <0.001∗∗
Lymphocytes
CD55 302 ±147 350 ± 121 0.041∗
CD59 24 (13–31) 30 (25–38) 0.012∗
CD35 23 (21–28) 28 (21–59) 0.053
CD46 62 (49–77) 79 (65–97) <0.001∗∗∗∗
Monocytes
CD55 953 ± 313 1057 ± 241 0.021∗
CD59 23 (18–33) 22 (15.5–33) 0.422∗
CD46 74 ± 21 78 ± 16 0.217
CD35 122 (66.2–202) 138 (85–198) 0.296∗∗
RBC
CD55 188 ± 44 201 ± 43 0.153
CD59 73 (53–110) 112 (102.5–148) <0.001∗∗
CD35 9.1 ± 2.5 15 ± 5.0 <0.001∗∗
∗Signiﬁcant statistical diﬀerence (P < 0.05).
∗∗Signiﬁcant statistical diﬀerence (P < 0.001).
aMedia ± SD or median (25–75 interquartile range).
bMann-Whitney U test or Student’s t-test.
may be due to their consumption trying to protect the
cell against complement-mediated lysis, perhaps triggered by
speciﬁc autoantibodies.
On lymphocytes, the CD55, CD59, and CD46 MFI
showed signiﬁcant diﬀerences between SLE and controls.
Lymphopenic patients presented the lower expression of
these Cregs. Similarly to our results, Garcia-Valladares et al.
[19] investigated the MFI of CD55 and CD59 in T and B
lymphocytes from SLE patients with lymphopenia. Both T
and B cells from lymphopenic patients showed decreased
membrane expression of CD55 and CD59 when compared
to controls. Tsunoda et al. [20] found that the proportion
of CD59 on activated T CD8+ lymphocytes in SLE patients
was signiﬁcantly reduced compared to controls and that it
could be correlated with disease activity and to be involved
in the induced apoptosis of these cells. Our data showed that
thedecreasedexpressionwasunrelatedtodiseaseactivityand
accumulated damage using SLEDAI and SLICC, as has been
reported [19, 21], but demonstrated that the lower the C3
level and consequently the greater complement activation,
the lower the expression of CD55 on lymphocytes in these
patients.
TheMFIsofCD59andCD35onRBCsfromSLEpatients
were signiﬁcantly reduced when compared to healthy con-
trols, but this deﬁciency does not seem to be associated with
anemia or autoimmune hemolytic anemia (AIHA), since
the nonanemic and patients with no secondary AIHA also
demonstrated reduced CD59 and CD35 MFI on their red
cells. Our data about the decreased CD35 expression on RBC
from SLE patients corroborate the ﬁndings of the literature
[12–16]. Furthermore, we found that the low expression of
CD35 in SLE patients was correlated with low C4 levels.
The diminished expression of CD59 on RBCs from SLE
patients with secondary AIHA was previously reported by
Richaud-Patin et al. [17]. However, in contrast with our
results, SLE patients with no AIHA exhibited a normal
expression of these molecules. It is important to mention
that the number of patients evaluated in our study with and
without AIHA was 28 and 72, respectively, which is much
greater than that of the study of Richaud-Patin et al.
WealsoobservedadecreasedCD35andCD59expression
on RBCs from SLE patients with nephritis (n = 45) (P<
0.05, data not shown). This ﬁnding corroborates in part
the ﬁndings of Arora et al. [18], who have demonstrated
that, in 15 lupus nephritis patients, the expression of CD35
was signiﬁcantly reduced compared to the expression on
erythrocytes from normal individuals. On the other hand,
these authors observed that CD55 and CD59 levels were
highly elevated in RBCs, in contrast with our results.
The cause of this generally decreased expression of Creg
proteins in SLE blood cells is still unclear. Richaud-Patin et
al. [17] have hypothesized that the diminished expression of
CD55 and CD59 proteins on red cells might be due either
to the impaired synthesis of the GPI (glycosylphosphatidyli-
nositol) anchor or to the abnormal coupling of the protein
to the membrane on red blood cell precursors. However, our
ﬁndings do not support these hypotheses, since in that case
the expression of Cregs would be uniformly reduced on all
blood cells, while diﬀerent patterns of diminished expression
depending on each cell type were observed in our study.
A decline in CD35 expression at both mRNA transcript
and protein level in SLE has been described, and it has
been suggested to be acquired [26]. However, nothing is
known about the factors involved in this downregulation6 Clinical and Developmental Immunology
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Figure 2: Creg surface expression of lymphocytes cell. The ﬁgure displays mean ﬂuorescence intensity (MFI) of CD55, CD59, CD46, and
CD35 on gated neutrophil from SLE patients with lymphopenia, without lymphopenia, and controls. Median and interquartile range from
all subjects studied in each group were shown. ∗Signiﬁcant statistical diﬀerence (P<0.05).
of CD35 gene expression [27]. Lach-Triﬁlieﬀ et al. [28]
demonstrated that there is no lack of CD35 expression on
young RBC (reticulocytes), in which CD35 is known to be
low, and in most cases the low CD35 on RBC is due to an
accelerated loss occurring in the circulation. Holme et al.
showed that erythrocyte CD35 numbers are reduced during
periods of increased disease activity and tend to return to
normal during remission [29].
The fact that there was an association of decreased Creg
expression with disease activity, low complement levels,
and decreased peripheral blood cell numbers in our study
indicates that the mechanism is related to the disease itself.
The production of autoantibodies against speciﬁc cell self-
antigens, Creg consumption, and complement-mediated
lysis may be the most plausible explanation, as has also
been partially suggested by other studies [5, 21, 30]. On
the other hand, the use of immunosuppressive drugs may
have inﬂuenced our results, being a limiting factor in our
study and because of the nonhomogenous treatments and
multiples therapies was limited to determine the clear
association of a speciﬁc drugs with Creg decrease and/or
cytopenia. We believe that the random inclusion of patients
can reduce this inﬂuence if it really exists.
The decreased expression of the Cregs may also involve
other functions of these proteins. For instance, CD59 has
been implicated in the process of signal transduction and
T-cell activation [31], and it has been reported that CD59
cross-linking induces internalization of this molecule and
endocytosis of the lymphocyte membrane [32]. By another
suggestion,itseemsthattheepitopesagainstwhichthemon-
oclonal antibodies are directed somehow express themselves
in a diﬀerential manner, depending on the cells’ activation
state [33].
In conclusion, it was evident that there are diﬀerences in
the patterns of expression of Creg proteins on the peripheral
blood cells from SLE patients, since the diminished MFIClinical and Developmental Immunology 7
Anemic SLE Non-anemic SLE Control
300
250
200
150
100
50
0
Group
C
D
5
5
 
M
F
I
(a)
700
600
500
400
300
200
100
0
C
D
5
9
 
M
F
I
Anemic SLE Non-anemic SLE Control
Group
∗
∗
(b)
35
30
25
20
15
10
5
0
Anemic SLE Non-anemic SLE Control
Group
C
D
3
5
 
M
F
I
∗
∗
(c)
Figure 3: Creg surface expression of RBC. The ﬁgure displays mean ﬂuorescence intensity (MFI) of CD55, CD59, CD46, and CD35 on gated
RBC from SLE patients with anemia, without anemia, and controls. Median and interquartile range from all subjects studied in each group
were shown. ∗Signiﬁcant statistical diﬀerence (P<0.05).
expressions of all Cregs proteins were found on neutrophils
cells; CD55, CD59, and CD46 on lymphocytes; CD55 on
monocytes; CD59 and CD35 on RBC. Moreover, these
diﬀerences, even for the lower most part, seem to correlate
with disease activity, complement activation, and blood cell
cytopenias. The cause of the decreased expression on cell
surface from SLE patients is not yet established, and the
mechanisms by which cells are destroyed or sequestered
remain rather obscure. We believe this is an adaptive
phenomenonthathappensduetoaconsumptionoftheCreg
proteins when trying to prevent complement-mediated cell
lysis. Moreover, the fact that each of these four hemopoietic
lineagesmightshowunderexpressionofCregsindependently
from the others suggests the participation of diﬀerent
physiopathologic processes. Deeper understanding of these
processes, and the role of Cregs, could be important for the
development of novel therapies for the blood cell involve-
ment in SLE and other autoimmune-mediated diseases.
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